X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (487) 487
Publication (91) 91
Patent (5) 5
Book Chapter (3) 3
Conference Proceeding (3) 3
Book Review (2) 2
Dissertation (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (192) 192
index medicus (132) 132
hematology (113) 113
middle aged (92) 92
multiple myeloma (92) 92
female (90) 90
male (90) 90
oncology (90) 90
aged (80) 80
multiple myeloma - genetics (78) 78
prognosis (71) 71
adult (67) 67
life sciences (57) 57
cancer (53) 53
multiple myeloma - drug therapy (49) 49
bortezomib (46) 46
stem-cell transplantation (44) 44
abridged index medicus (43) 43
survival (43) 43
multiple myeloma - mortality (39) 39
multiple myeloma - pathology (39) 39
in situ hybridization, fluorescence (38) 38
multiple myeloma - therapy (31) 31
antineoplastic combined chemotherapy protocols - therapeutic use (30) 30
therapy (29) 29
treatment outcome (29) 29
dexamethasone (28) 28
expression (28) 28
translocation, genetic (28) 28
chromosome aberrations (27) 27
cytogenetics (27) 27
disease-free survival (27) 27
aged, 80 and over (26) 26
in-situ hybridization (25) 25
multiple-myeloma (25) 25
abnormalities (24) 24
lenalidomide (23) 23
multiple myeloma - diagnosis (23) 23
survival rate (23) 23
mutation (22) 22
thalidomide (22) 22
chemotherapy (21) 21
[ sdv.can ] life sciences [q-bio]/cancer (20) 20
[sdv.can]life sciences [q-bio]/cancer (20) 20
survival analysis (20) 20
dexamethasone - administration & dosage (19) 19
myeloma (19) 19
retrospective studies (18) 18
risk factors (18) 18
article (17) 17
gene (17) 17
intergroupe francophone (17) 17
transplantation (17) 17
care and treatment (16) 16
leukemia (16) 16
multiple myeloma - immunology (16) 16
diagnosis (15) 15
genetic aspects (15) 15
genetics & heredity (15) 15
monoclonal gammopathy (15) 15
transplantation, autologous (15) 15
adolescent (14) 14
follow-up studies (14) 14
genomics (14) 14
neoplasm staging (14) 14
thalidomide - analogs & derivatives (14) 14
[sdv]life sciences [q-bio] (13) 13
gene expression profiling (13) 13
gene expression regulation, neoplastic (13) 13
hemic and lymphatic diseases (13) 13
minimal residual disease (13) 13
patients (13) 13
remission induction (13) 13
stem cell transplantation (13) 13
t (13) 13
thalidomide - administration & dosage (13) 13
analysis (12) 12
antineoplastic agents - therapeutic use (12) 12
chromosomes, human, pair 14 - genetics (12) 12
disease progression (12) 12
hematopoietic stem cell transplantation (12) 12
recurrence (12) 12
risk (12) 12
102 (11) 11
antineoplastic combined chemotherapy protocols - adverse effects (11) 11
chromosome deletion (11) 11
chromosomes, human, pair 14 (11) 11
elderly-patients (11) 11
gene expression (11) 11
high-dose therapy (11) 11
kaplan-meier estimate (11) 11
translocations (11) 11
aneuploidy (10) 10
bone marrow (10) 10
cell line, tumor (10) 10
child (10) 10
genes (10) 10
hematology, oncology and palliative medicine (10) 10
immunoglobulin heavy chains - genetics (10) 10
karyotyping (10) 10
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 02/2019, Volume 133, Issue 7, pp. 621 - 621
Journal Article
Blood, 12/2018
Journal Article
Revue Francophone des Laboratoires, ISSN 1773-035X, 04/2019, Volume 2019, Issue 511, pp. 50 - 57
Grâce à l’avènement des nouveaux outils de la génomique, il est aujourd’hui devenu évident que le myélome multiple n’est pas une maladie unique mais une... 
myélome multiple | séquençage de nouvelle génération | multiple myeloma | adaptation thérapeutique | next-generation sequencing | therapeutic adaptation | sous-clones | subclones | 17p deletion | délétion 17p
Journal Article
Revue Francophone des Laboratoires, ISSN 1773-035X, 04/2019, Volume 2019, Issue 511, p. 50
Journal Article
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting, 2016, Volume 35, Issue 36, pp. e425 - e430
The wealth of data recently generated highlights that minimal residual disease (MRD)-negative status can be achieved in a large proportion of patients. These... 
Journal Article
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, ISSN 1520-4391, 2010, Volume 2010, Issue 1, pp. 489 - 493
Journal Article
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 11/2016, Volume 22, Issue 22, pp. 5434 - 5442
Multiple myeloma (MM) is a plasma cell malignancy characterized by molecular and clinical heterogeneity. The outcome of the disease has been dramatically... 
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 03/2011, Volume 17, Issue 6, pp. 1234 - 1242
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2017, Volume 35, Issue 25, pp. 2863 - 2865
Journal Article
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 05/2018, Volume 38, Issue 38, pp. 675 - 680
In the past 15 years, significant improvements in overall survival have been observed in multiple myeloma (MM), mainly due to the availability of novel drugs... 
Multiple Myeloma - therapy | Genomics - methods | Humans | Risk Factors | Multiple Myeloma - genetics
Journal Article
Hématologie, ISSN 1264-7527, 11/2016, Volume 22, Issue 6, pp. 393 - 394
Journal Article
Hematologie, ISSN 1264-7527, 11/2016, Volume 22, Issue 6, pp. 393 - 394
Journal Article
Medecine/Sciences, ISSN 0767-0974, 11/2017, Volume 33, Issue 11, pp. 939 - 941
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2017, Volume 376, Issue 14, pp. 1311 - 1320
In this trial, 700 patients with myeloma were randomly assigned to receive RVD therapy (lenalidomide, bortezomib, and dexamethasone) with or without autologous... 
DIAGNOSED MULTIPLE-MYELOMA | MEDICINE, GENERAL & INTERNAL | PHASE-III | AUTOLOGOUS TRANSPLANTATION | DARATUMUMAB MONOTHERAPY | INITIAL TREATMENT | FOLLOW-UP | PREDNISONE PLUS THALIDOMIDE | RANDOMIZED CONTROLLED-TRIAL | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Induction Chemotherapy | Male | Transplantation, Autologous | Stem Cell Transplantation | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Adult | Female | Maintenance Chemotherapy | Thalidomide - adverse effects | Dexamethasone - administration & dosage | Lenalidomide | Kaplan-Meier Estimate | Combined Modality Therapy | Thalidomide - administration & dosage | Disease-Free Survival | Bortezomib - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bortezomib - adverse effects | Aged | Usage | Care and treatment | Bortezomib | Dexamethasone | Patient outcomes | Multiple myeloma | Transplantation of organs, tissues, etc | Dosage and administration | Autografts | Gastrointestinal tract diseases | Minimal residual disease | Stem cell transplantation | Peripheral neuropathy | Patients | Chemotherapy | Melphalan | Thromboembolism | Neutropenia | Life Sciences | Cancer
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.